Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of “Buy” from Analysts
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) has been assigned an average recommendation of “Buy” from the six analysts that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued a report on the stock in the […]
More Stories
Berkshire Hathaway Inc. (NYSE:BRK-B) Major Shareholder Sells $269,261,980.61 in Stock
Berkshire Hathaway Inc. (NYSE:BRK-B – Get Free Report) major shareholder Berkshire Hathaway Inc sold 6,349,021 shares of the stock in...
SAP (NYSE:SAP) PT Raised to $248.00 at BMO Capital Markets
SAP (NYSE:SAP – Free Report) had its price objective hoisted by BMO Capital Markets from $237.00 to $248.00 in a...
StockNews.com Upgrades GameStop (NYSE:GME) to “Sell”
StockNews.com upgraded shares of GameStop (NYSE:GME – Free Report) to a sell rating in a research note released on Tuesday....
Needham & Company LLC Raises NXP Semiconductors (NASDAQ:NXPI) Price Target to $300.00
NXP Semiconductors (NASDAQ:NXPI – Free Report) had its price target boosted by Needham & Company LLC from $280.00 to $300.00...
HCA Healthcare (NYSE:HCA) Price Target Raised to $390.00
HCA Healthcare (NYSE:HCA – Free Report) had its price objective raised by Truist Financial from $375.00 to $390.00 in a...
DA Davidson Raises MarineMax (NYSE:HZO) Price Target to $37.00
MarineMax (NYSE:HZO – Free Report) had its price target lifted by DA Davidson from $34.00 to $37.00 in a research...